한빛사
>
한빛사논문
한빛사논문
5
- 조회220
J. Control. Release, Jan 26 2025, S0168-3659(25)00070-7 | https://doi.org/10.1016/j.jconrel.2025.01.060
Receptor-ligand interactions for optimized endocytosis in targeted therapies
Yejin Sung a,1, Youngjin Choi a,1, Eun Sun Kim b, Ju Hee Ryu a,c, Ick Chan Kwon a,c
aMedicinal Materials Research Center, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea
bDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University College of Medicine, Seoul 20841, Republic of Korea
cKU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul 02841, Republic of Korea
1These authors contributed to the work equally.
Corresponding authors : Ju Hee Ryu, Ick Chan Kwon
aMedicinal Materials Research Center, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea
bDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University College of Medicine, Seoul 20841, Republic of Korea
cKU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul 02841, Republic of Korea
1These authors contributed to the work equally.
Corresponding authors : Ju Hee Ryu, Ick Chan Kwon
Abstract
Receptor-mediated endocytosis plays a crucial role in the success of numerous therapies and remains central to advancing drug development. This process begins with ligand binding to specific receptors, triggering the internalization and intracellular trafficking of receptor-ligand complexes. These complexes are subsequently directed into distinct routes, either toward lysosomal degradation or recycling to the cell surface, with implications for therapeutic outcomes. This review examines receptor-ligand interactions as key modulators of endocytosis, emphasizing their role in shaping therapeutic design and efficacy. Advances in selecting receptor-ligand pairs and engineering ligands with optimized properties have enabled precise control over internalization, endosomal sorting, and trafficking, providing tailored solutions for diverse therapeutic applications. Leveraging these insights, strategies such as RNA-based therapies, antibody-drug conjugates (ADCs), and targeted protein degradation (TPD) platforms have been refined to selectively avoid or promote lysosomal degradation, thereby enhancing therapeutic efficacy. By bridging fundamental mechanisms of receptor-mediated endocytosis with innovative therapeutic approaches, this review offers a framework for advancing precision medicine.
논문정보
- Research article
- 2025년 01월 (BRIC 등록일 2025-02-17)
- 국내 연구진
- 바이오·의료융합 > 바이오·의료융합 기타
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
관련분야 논문보기
